Scientific & Regulatory Consulting•Toxicology & Product Safety
Request basket0
PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Gozetotide→

Gozetotide PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
1366302-52-4
Molecular formula
C44H62N6O17
Molecular weight
947 g/mol
Drug class
PSMA-targeting liganddiagnostic radiopharmaceutical component for gallium-68 PET imaging
Mechanism of action
The Glu-urea-Lys(Ahx) peptide ligand binds prostate-specific membrane antigen (PSMA) on prostate epithelial cells and commonly overexpressed on prostate cancer cells. When conjugated to the HBED-CC chelator and radiolabelled with gallium-68, the resulting radioconjugate enables PET visualisation of PSMA-expressing lesions.
Indications / reported uses
  • Used as the active ligand in gallium Ga-68 gozetotide (PSMA-11) injection for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated PSA.
  • The unlabelled ligand is not itself a radioactive imaging agent; diagnostic imaging requires the labelled gallium-68 product.

Sources: https://www.ema.europa.eu/en/medicines/human/EPAR/locametz · https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=357655a4-b3ee-4ea1-a1ea-50d4686546bb · https://www.cancer.gov/publications/dictionaries/cancer-drug/def/gallium-ga-68-gozetotide · FDA product information

View request basketPrefer email? [email protected]
PDE / ADE derivationOEL derivationOEB / OHC bandingRequest basket0
Substance information

Drug class, mechanism of action and general use cases

Drug class

PSMA-targeting ligand; diagnostic radiopharmaceutical component for gallium-68 PET imaging

Mechanism of action

The Glu-urea-Lys(Ahx) peptide ligand binds prostate-specific membrane antigen (PSMA) on prostate epithelial cells and commonly overexpressed on prostate cancer cells. When conjugated to the HBED-CC chelator and radiolabelled with gallium-68, the resulting radioconjugate enables PET visualisation of PSMA-expressing lesions.

General use cases

  • Used as the active ligand in gallium Ga-68 gozetotide (PSMA-11) injection for PET imaging of PSMA-positive lesions in men with prostate cancer with suspected metastasis who are candidates for initial definitive therapy, or suspected recurrence based on elevated PSA.
  • The unlabelled ligand is not itself a radioactive imaging agent; diagnostic imaging requires the labelled gallium-68 product.

For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.

Assessment scope

Project-specific PDE/ADE and OEL/OEB support

Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.

  • PDE/ADE: critical effects, point of departure and justified adjustment factors.
  • OEL: inhalation hazards, exposure duration and workplace conditions.
  • OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
  • Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope

PDE/ADE and OEL/OEB assessment

ReguSight provides project-specific support for Gozetotide PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Gozetotide Permitted Daily Exposure (PDE) report (the Gozetotide PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Gozetotide Occupational Exposure Limit (OEL) report (the Gozetotide OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.